Background
Significant Gap in cardiac rehabilitation availability and participation
Reimbursement of cardiac rehabilitation
Government reimbursement
Insurance company reimbursement
Advocacy for cardiac rehabilitation
Cardiac rehabilitation-specific advocacy
Method of communication | Description |
---|---|
Key messages | This includes important messages that should be repeated often, and be easy to understand in order to gain support |
Letter-writing and/or phone call campaigns | This includes campaigns towards policy makers which are well-controlled and coordinated. |
Meetings with policy-makers, either in private or in public | This provides prime opportunity to personalize the cause they are supporting by sharing their perspective, story, and passion. |
Media messaging on the issue (including social media and websites) | This includes sharing stories on CR topics (e.g., patient’s personal story of triumphs or struggles with heart disease, new findings of scientific significance to the field, or expert opinions about urgent public health concerns or heart-related illnesses of public figures) through various media sources |
Country | What did they do? | What did they achieve? |
---|---|---|
Iran | Developed a CR research center Enhanced research Discussion and seminars with policy-makers & insurance companies | Directive from the Ministry of Health that all components of CR will be reimbursed by insurance companies Improved CR attendance |
Qatar | Developed clinical services and formed a CR planning committee Collaborating with other organizations for phase 3 CR | Formed the working group of Qatar Association for Cardiovascular Prevention and Rehabilitation Improved CR referrals |
United Kingdom | Evidence-based campaigning for reimbursement Emphasis from national guidelines on CR and formation of standards for delivery of CR | Created a National Commissioning Guide and Tool-kit to fund CR Improved CR referrals |
United States of America | AACVPR developed performance measures for CR Provided evidence-based campaigns from long-term studies Conducted government sponsored projects showing cost- effectiveness of CR | Developed performance measures of CR HF included under indications for CR referral State health plans to cover essential health benefits related to CR |
The need for cardiac rehabilitation
Economic impact of cardiovascular disease
Economic impact of cardiac rehabilitation
Author (year) | Intervention | Patient population | Estimated savings |
---|---|---|---|
Ades et al. (1997) [46] | CR versus with other post-MI treatment interventions | Post MI or revascularization | CR was found to result in savings of 2,130 $/YLS in 1980, which was projected to be 4,950 $/YLS for 1995 |
Johanneson et al. (1997) [47] | Statins (i.e., Simvastatin) versus no statins | Angina or MI | Simvastatin use resulted in $3,800 to $27,400 cost per year of life gained |
Cleland et al. (1997) [48] | CABG + Medical therapy + aspirin versus CABG + medical therapy + aspirin + statin versus medical+aspirin+statin versus medical + aspirin | Chronic stable angina | $36,709, $55,156 and $23,730 per QALY for each comparison over 5 years |
Chan et al. (2007) [49] | High intensity versus low intensity statin | Acute coronary syndrome, Chronic coronary disease | From $20,000 to $35,000 if cost difference of statins is between $2 and $3.50 From $70,000 to $125,000 if cost difference of statins is between $2 and $3.50 |
Dendale et al. (2008) [50] | CR versus no CR | Post PCI | Reduction in total health care costs with CR (€4,862/patient versus €5,498 Euro/patient) |
Weinbtraub et al. (2008) [51]a
| PCI and medical therapy versus Medical therapy alone | Stable angina | $168,000 to $300,000 per QALY gained with PCI |
Wilson et al. (2012) [52] | Smoking cessation with varenicline plus counseling versus counseling only | CVD | Savings ranging from €5151 - €6120 per QALY gained |
Smith et al. (2013) [53] | Implantable cardiac defibrillator versus no defibrillator | Primary prevention of sudden death in patients with left ventricular ejection fraction <40% (ischemic and non-ischemic) | €43,993 per QALY gained compared to no defibrillator |